Exercise and Nasal Insulin Spray Tested in Type 2 Diabetes
Tests nasal insulin spray with exercise in adults with type 2 diabetes.
Key facts
- Who runs it
- Rutgers, The State University of New Jersey
- Where
- New Brunswick and Piscataway, United StatesSee the 4 sites
- Trial code
- Registry title
- Exercise and Intranasal Insulin in Type 2 Diabetes
- Status
- Recruiting
- Phase
- Phase 2/3
- People taking part
- 60 people, planned
- Started
- 3 Aug 2026
- Expected to end
- 31 May 2029
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Intranasal Insulin
- Intranasal Placebo
- High Intensity Exercise
- Record updated
- 30 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 55-80 with type 2 diabetes who have good memory scores and do little exercise now.
- Age
- 55 to 80 years
- Sex
- Men and women
- Disease stage
- Type 2 diabetes confirmed by HbA1c >6.5% (48 mmol/mol) and fasting glucose >126 mg/dl (7 mmol/L). No type 1 diabetes.
- Earlier treatment
- Must have been prescribed metformin, GLP-1 agonists, TZDs, DPP-IV inhibitors, Acarbose or SGLT-2 inhibitors for >6 months.
- Biomarker or test result
- MOCA score of 26 or higher. Body mass index (BMI) of 25 to 40 kg/m2.
Main reasons for not taking part
- Dementia or a neurologic disease such as Parkinson's
- BMI above 40 or below 25 kg/m2
- Smokers, or people who quit smoking less than 2 years ago
- Pregnant or nursing women
- Conditions that rule out an MRI scan, such as metal implants or claustrophobia
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Male or female 55-80 years old
- Type 2 diabetes diagnosis or confirmation HbA1c >6.5% and fasting glucose >126 mg/dl
- Individuals prescribed metformin, GLP-1 agonists (oral/injectable), TZDs, DPP-IV inhibitors, Acarbose, SGLT-2 inhibitors >6 months
- MOCA ≥26
- Body mass index (BMI) ≥25 and ≤40 kg/m2
- Not diagnosed with Type 1 diabetes
- Not currently engaged in <90 min/wk of exercise
Who cannot take part
- A diagnosis of dementia
- Neurologic disease (e.g. Parkinson's, autonomic neuropathy, etc.)
- Participants with a history of significant metabolic, cardiac, cerebrovascular, hematological, pulmonary, gastrointestinal, liver, renal, or endocrine disease or cancer that in the investigator's opinion would interfere with or alter the outcome measures, or impact subject safety
- Major psychiatric disorders (e.g. psychosis, bipolar disorder, major depression, alcohol/substance abuse)
- History of head trauma or loss of consciousness in last 5 years
- Known contraindications for MR imaging:; History of head trauma or neurosurgery, or neurological disorder (other than headaches or peripheral nerve disease) as these may impact neuroimaging results; Ferrous material implanted in or on the body, including flakes or filings, surgical clips, bullets, or electrical devices such as a pacemaker, or nonremovable ferrous jewelry (fillings in teeth and permanent retainers are permitted); Fillings and permanent retainers do not provide a safety risk and are not general exclusions. However, upper retainers may cause artifacts in ventral frontal regions and therefore may be an exclusion for some studies; Individuals with surgical pins or plates above the neck are excluded. Surgical pins or plates below the neck are exclusions, except when the material is fixed to bone, and considered acceptable by the Reference Manual for Magnetic Resonance Safety. Implants and Devices, 2020 Edition. Almost all recent orthopedic implants are made of materials that are not ferromagnetic and therefore are safe for scanning, and even though some screws are still made of ferromagnetic materials these are firmly screwed into bone. In cases where the material is unknown or deemed unsafe for scanning by the Reference Manual for Magnetic Resonance Safety. Implants and Devices the participant will be excluded; History of eye injury involving metallic materials, shavings in eyes, or welding without a face mask; Lead/iron tattoos; Claustrophobia (history of significant anxiety in closed places); Back problem that would prevent the subject from laying still comfortably for up to 90 minutes; Deafness
- Hypertriglyceridemia (400 mg/dl) and hypercholesterolemic (>260 mg/dl) subjects
- Individuals who are smokers or who have quit smoking (<2 years)
- Intolerance to insulin
- Morbidly obese patients (BMI >40 kg/m2) and lean patients (BMI <25 kg/m2)
- >2 kg weight change in past 6 months
- Participants who have been recently active (>90 min of moderate/high intensity exercise)
- Uncontrolled Hypertensive (>160/100 mmHg)
- Pregnant (as evidenced by positive pregnancy test) or nursing women
- Participants with contraindications to participation in an exercise training program
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 55 and 80 years old?
Where in United States
- Institute for Food, Nutrition, and HealthNew Brunswick, United StatesContact: Sue Shapses, PhDTaking people
- Robert Wood Johnson University Hospital Clinical Research CenterNew Brunswick, United StatesContact: Fei ChenTaking people
- Rutgers University Loree GymnasiumNew Brunswick, United StatesContact: Steven Malin, PhDTaking people
- Center for Advanced Human Brain Imaging ResearchPiscataway, United StatesContact: David Zald, PhDTaking people
About the trial
What the trial wants to find out
About 6.5 million adults in the United States who are 65 or older have dementia.
Read full original descriptionShow less
While the exact cause of dementia is not known, it may be due to changes in the brain. Further, risk may be higher when the brain does not respond to insulin. Indeed, brain insulin resistance has emerged as a pathologic factor affecting memory, executive function as well as systemic glucose control. Regular aerobic exercise may help reduce the risk of dementia by increased blood flow to the brain and help the brain respond better to insulin. In addition, giving insulin through a nose spray (called intranasal insulin) may also help with thinking and memory. However, it is unknown if using both exercise and intranasal insulin is best for the brain.
The 2 groups in the trial
- HiEx with Intranasal PlaceboPlacebo, for comparison
Treatment: Intranasal Placebo and High Intensity Exercise
- HiEx with Intranasal InsulinExisting treatment, for comparison
Treatment: Intranasal Insulin and High Intensity Exercise
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effects of Intranasal Insulin Plus Exercise Training on Brain Blood Flow, Neuronal Insulin Signaling, and Cognition in Adults With Type 2 Diabetes
- Plain-language title
- Exercise and Nasal Insulin Spray Tested in Type 2 DiabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07675499, who can take part
- Record updated
- 30 June 2026